| Anesthesia |
Preaquisition |
7 |
3 |
2 |
0 |
0 |
1 |
| Antibiotic |
Preaquisition |
0 |
0 |
0 |
0 |
0 |
0 |
| Biomarker level |
Preaquisition |
65 |
39 |
44 |
13 |
0 |
14 |
| Blood loss amount |
Preaquisition |
0 |
0 |
0 |
0 |
0 |
4 |
| Blood pressure |
Preaquisition |
4 |
1 |
2 |
0 |
0 |
1 |
| Cause of death |
Preaquisition |
0 |
0 |
0 |
0 |
0 |
9 |
| Diagnosis/ patient condition |
Preaquisition |
303 |
134 |
213 |
50 |
12 |
201 |
| Duration of anesthesia |
Preaquisition |
2 |
0 |
1 |
0 |
0 |
0 |
| Intra-operative blood administration |
Preaquisition |
1 |
0 |
1 |
0 |
0 |
0 |
| Intra-operative fluid administration |
Preaquisition |
1 |
1 |
0 |
0 |
0 |
0 |
| Non-invasive procedure type |
Preaquisition |
0 |
0 |
1 |
1 |
1 |
0 |
| Other drugs |
Preaquisition |
76 |
19 |
55 |
7 |
2 |
22 |
| Patient age |
Preaquisition |
119 |
57 |
61 |
14 |
9 |
77 |
| Patient body mass index |
Preaquisition |
16 |
6 |
14 |
0 |
0 |
5 |
| Patient diet |
Preaquisition |
20 |
9 |
17 |
2 |
0 |
1 |
| Patient gender |
Preaquisition |
131 |
71 |
77 |
23 |
11 |
62 |
| Patient genotype |
Preaquisition |
17 |
2 |
9 |
0 |
0 |
7 |
| Patient race |
Preaquisition |
8 |
3 |
3 |
0 |
2 |
6 |
| Patient weight |
Preaquisition |
1 |
0 |
0 |
0 |
0 |
0 |
| Postmortem condition(s) |
Preaquisition |
1 |
0 |
1 |
0 |
0 |
6 |
| Postmortem interval |
Preaquisition |
11 |
0 |
1 |
0 |
0 |
89 |
| Prior patient medical condition |
Preaquisition |
2 |
1 |
0 |
0 |
1 |
6 |
| Prognostic factor |
Preaquisition |
18 |
8 |
22 |
2 |
0 |
51 |
| Rapidity of death |
Preaquisition |
1 |
0 |
0 |
0 |
0 |
17 |
| Study design |
Preaquisition |
1 |
1 |
2 |
0 |
0 |
0 |
| Surgery duration |
Preaquisition |
0 |
0 |
0 |
0 |
0 |
2 |
| Surgical procedure type |
Preaquisition |
5 |
1 |
2 |
0 |
0 |
10 |
| Warm ischemia time |
Preaquisition |
0 |
0 |
0 |
0 |
0 |
17 |
| Anatomical location of blood draw |
Biospecimen Acquisition |
86 |
21 |
32 |
0 |
0 |
0 |
| Anticoagulant |
Biospecimen Acquisition |
305 |
129 |
222 |
2 |
1 |
29 |
| Biospecimen location |
Biospecimen Acquisition |
65 |
34 |
52 |
29 |
27 |
255 |
| Cannulation |
Biospecimen Acquisition |
14 |
3 |
3 |
0 |
0 |
1 |
| Cold ischemia time |
Biospecimen Acquisition |
2 |
0 |
0 |
0 |
0 |
115 |
| Data management |
Biospecimen Acquisition |
2 |
1 |
0 |
0 |
0 |
0 |
| Locale of biospecimen collection |
Biospecimen Acquisition |
11 |
5 |
3 |
3 |
0 |
11 |
| Method of cell acquisition |
Biospecimen Acquisition |
2 |
0 |
0 |
1 |
13 |
49 |
| Method of fluid acquisition |
Biospecimen Acquisition |
128 |
35 |
52 |
37 |
19 |
16 |
| Method of tissue acquisition |
Biospecimen Acquisition |
1 |
0 |
0 |
1 |
0 |
137 |
| Needle gauge |
Biospecimen Acquisition |
18 |
7 |
5 |
0 |
0 |
25 |
| Organ measurements |
Biospecimen Acquisition |
1 |
1 |
0 |
0 |
0 |
7 |
| Pathology ink |
Biospecimen Acquisition |
0 |
0 |
0 |
0 |
0 |
3 |
| Patient posture |
Biospecimen Acquisition |
22 |
10 |
13 |
2 |
1 |
1 |
| Pre-preservation condition |
Biospecimen Acquisition |
4 |
0 |
2 |
0 |
0 |
8 |
| Time of biospecimen collection |
Biospecimen Acquisition |
176 |
70 |
120 |
35 |
14 |
23 |
| Type of collection container/solution |
Biospecimen Acquisition |
329 |
134 |
201 |
8 |
5 |
23 |
| Unspecified ischemia time |
Biospecimen Acquisition |
0 |
0 |
0 |
0 |
0 |
3 |
| Aliquot sequential collection |
Biospecimen Aliquots and Components |
51 |
16 |
19 |
8 |
1 |
9 |
| Aliquot size/volume |
Biospecimen Aliquots and Components |
107 |
45 |
64 |
12 |
4 |
82 |
| Biospecimen components |
Biospecimen Aliquots and Components |
95 |
44 |
62 |
22 |
3 |
29 |
| Biospecimen heterogeneity |
Biospecimen Aliquots and Components |
7 |
1 |
4 |
2 |
0 |
52 |
| Biospecimen mixing |
Biospecimen Aliquots and Components |
32 |
10 |
20 |
3 |
0 |
3 |
| Blood and blood products |
Biospecimen Aliquots and Components |
420 |
316 |
401 |
6 |
1 |
82 |
| Blood processing method |
Biospecimen Aliquots and Components |
57 |
1 |
19 |
1 |
0 |
29 |
| Cell capture method |
Biospecimen Aliquots and Components |
14 |
1 |
0 |
0 |
0 |
22 |
| Cell number |
Biospecimen Aliquots and Components |
9 |
0 |
0 |
1 |
0 |
6 |
| Centrifugation |
Biospecimen Aliquots and Components |
414 |
178 |
347 |
35 |
11 |
30 |
| Filtration |
Biospecimen Aliquots and Components |
17 |
6 |
15 |
6 |
1 |
4 |
| Hemolysis |
Biospecimen Aliquots and Components |
65 |
31 |
50 |
0 |
0 |
2 |
| Number of cell passages |
Biospecimen Aliquots and Components |
0 |
0 |
0 |
0 |
0 |
2 |
| pH |
Biospecimen Aliquots and Components |
3 |
3 |
4 |
26 |
1 |
24 |
| Tissue section adhesion |
Biospecimen Aliquots and Components |
0 |
0 |
0 |
0 |
0 |
6 |
| Type of slide |
Biospecimen Aliquots and Components |
0 |
0 |
0 |
0 |
0 |
44 |
| Clearing agent |
Biospecimen Preservation |
0 |
0 |
0 |
0 |
0 |
9 |
| Clearing duration/condition |
Biospecimen Preservation |
0 |
0 |
0 |
0 |
0 |
12 |
| Concentration of fixative |
Biospecimen Preservation |
3 |
0 |
0 |
2 |
1 |
13 |
| Conditions during fixation/preservation |
Biospecimen Preservation |
2 |
0 |
0 |
0 |
0 |
0 |
| Cooling or freezing method/ rate |
Biospecimen Preservation |
8 |
1 |
8 |
3 |
2 |
30 |
| Dehydration duration/condition |
Biospecimen Preservation |
1 |
1 |
2 |
0 |
0 |
14 |
| Dehydration reagent |
Biospecimen Preservation |
0 |
0 |
0 |
0 |
0 |
6 |
| Duration of tissue/ specimen processing |
Biospecimen Preservation |
1 |
0 |
1 |
0 |
0 |
20 |
| Embedding duration/condition |
Biospecimen Preservation |
0 |
0 |
0 |
0 |
0 |
13 |
| Embedding medium |
Biospecimen Preservation |
0 |
0 |
0 |
0 |
0 |
26 |
| Enzyme inhibitor |
Biospecimen Preservation |
0 |
0 |
0 |
1 |
0 |
1 |
| Fixative additive/buffer |
Biospecimen Preservation |
16 |
4 |
8 |
8 |
2 |
18 |
| Fixative pH |
Biospecimen Preservation |
0 |
0 |
0 |
0 |
0 |
5 |
| Kinase inhibitor |
Biospecimen Preservation |
0 |
0 |
0 |
0 |
0 |
1 |
| Method of fixative delivery |
Biospecimen Preservation |
0 |
0 |
0 |
0 |
0 |
23 |
| Method of fixative removal |
Biospecimen Preservation |
0 |
0 |
0 |
0 |
0 |
1 |
| RNA stabilization method |
Biospecimen Preservation |
9 |
1 |
1 |
0 |
0 |
4 |
| Temperature of fixation/preservation |
Biospecimen Preservation |
2 |
0 |
1 |
0 |
0 |
26 |
| Time in fixative |
Biospecimen Preservation |
1 |
0 |
0 |
0 |
0 |
162 |
| Tissue to fixative ratio |
Biospecimen Preservation |
0 |
0 |
0 |
0 |
0 |
2 |
| Type of fixation/preservation |
Biospecimen Preservation |
239 |
93 |
156 |
90 |
12 |
537 |
| Volume/ concentration of preservative |
Biospecimen Preservation |
0 |
0 |
0 |
0 |
0 |
1 |
| Between site transportation method |
Storage |
54 |
12 |
26 |
3 |
1 |
22 |
| Freeze/thaw cycling |
Storage |
130 |
132 |
129 |
41 |
9 |
34 |
| Post-thaw duration |
Storage |
2 |
3 |
5 |
3 |
0 |
1 |
| Prefixation freezing |
Storage |
1 |
0 |
0 |
0 |
0 |
2 |
| Short-term storage solution |
Storage |
35 |
0 |
7 |
3 |
2 |
36 |
| Specimen transport duration/condition |
Storage |
68 |
15 |
26 |
4 |
1 |
12 |
| Specimen/sample transfer |
Storage |
0 |
0 |
0 |
0 |
0 |
0 |
| Storage conditions |
Storage |
108 |
45 |
69 |
19 |
4 |
48 |
| Storage duration |
Storage |
616 |
321 |
414 |
123 |
23 |
478 |
| Storage in ethanol (duration/condition) |
Storage |
0 |
0 |
0 |
0 |
1 |
1 |
| Storage temperature |
Storage |
401 |
230 |
306 |
106 |
20 |
150 |
| Storage under gas/vacuum |
Storage |
0 |
0 |
0 |
0 |
0 |
0 |
| Thaw duration |
Storage |
9 |
8 |
7 |
1 |
0 |
11 |
| Thaw temperature/condition |
Storage |
10 |
9 |
9 |
3 |
0 |
7 |
| Time at room temperature |
Storage |
296 |
102 |
159 |
29 |
12 |
77 |
| Type of storage container |
Storage |
59 |
33 |
28 |
8 |
0 |
8 |
| Within hospital transportation method |
Storage |
63 |
16 |
20 |
3 |
0 |
2 |
| Analyte isolation method |
Analyte Extraction and Purification |
106 |
40 |
118 |
33 |
5 |
193 |
| Analyte purification |
Analyte Extraction and Purification |
14 |
7 |
11 |
5 |
2 |
19 |
| Antigen retrieval |
Analyte Extraction and Purification |
0 |
0 |
0 |
1 |
0 |
57 |
| Between Site Variability |
Analyte Extraction and Purification |
1 |
0 |
0 |
0 |
0 |
0 |
| Cell/tissue permeabilization |
Analyte Extraction and Purification |
4 |
0 |
0 |
0 |
0 |
12 |
| Decalcification solution/ duration |
Analyte Extraction and Purification |
0 |
0 |
0 |
1 |
0 |
23 |
| Deparaffinization |
Analyte Extraction and Purification |
0 |
0 |
0 |
0 |
0 |
42 |
| Fat clearing |
Analyte Extraction and Purification |
0 |
0 |
0 |
0 |
0 |
1 |
| Filtration of purified DNA |
Analyte Extraction and Purification |
1 |
0 |
0 |
0 |
0 |
1 |
| HPLC elution time |
Analyte Extraction and Purification |
0 |
0 |
0 |
0 |
0 |
0 |
| Hydrolyzation |
Analyte Extraction and Purification |
0 |
0 |
0 |
0 |
0 |
0 |
| Incubation duration/condition |
Analyte Extraction and Purification |
9 |
2 |
7 |
0 |
0 |
25 |
| Nucleic acid digestion |
Analyte Extraction and Purification |
17 |
6 |
5 |
2 |
5 |
12 |
| Protease inhibitor |
Analyte Extraction and Purification |
19 |
16 |
23 |
12 |
6 |
0 |
| Protein digestion |
Analyte Extraction and Purification |
5 |
3 |
9 |
1 |
1 |
57 |
| Protein solubilization |
Analyte Extraction and Purification |
1 |
1 |
0 |
0 |
0 |
5 |
| Rehydration of dried sample/specimen |
Analyte Extraction and Purification |
5 |
1 |
7 |
0 |
2 |
7 |
| RNase inactivation |
Analyte Extraction and Purification |
4 |
4 |
2 |
0 |
0 |
1 |
| Sample mixing |
Analyte Extraction and Purification |
4 |
4 |
2 |
0 |
0 |
0 |
| Specimen format |
Analyte Extraction and Purification |
1 |
0 |
1 |
0 |
0 |
2 |
| Temperature of heat-induced retrieval |
Analyte Extraction and Purification |
1 |
0 |
0 |
0 |
0 |
23 |
| Tissue homogenization |
Analyte Extraction and Purification |
0 |
0 |
0 |
0 |
0 |
3 |
| Washing |
Analyte Extraction and Purification |
5 |
0 |
1 |
1 |
0 |
14 |
| pH |
Platform Specific Methodology - 1D/2D gels |
1 |
0 |
0 |
0 |
0 |
0 |
| Signal amplification |
Platform Specific Methodology - 1D/2D gels |
1 |
0 |
0 |
0 |
0 |
0 |
| Technology platform |
Platform Specific Methodology - 1D/2D gels |
2 |
1 |
1 |
2 |
0 |
1 |
| Type of tissue stain |
Platform Specific Methodology - 1D/2D gels |
0 |
0 |
0 |
0 |
0 |
2 |
| Antibody dilution/concentration |
Platform Specific Methodology - Antibody microarray |
1 |
1 |
1 |
0 |
0 |
0 |
| Antibody dilution/concentration |
Platform Specific Methodology - Antiglobulin test |
0 |
0 |
0 |
0 |
0 |
1 |
| Targeted peptide/protein |
Platform Specific Methodology - Antiglobulin test |
0 |
0 |
0 |
0 |
0 |
1 |
| Technology platform |
Platform Specific Methodology - Antiglobulin test |
0 |
0 |
0 |
0 |
0 |
1 |
| Nucleic acid amplification |
Platform Specific Methodology - Array CGH |
0 |
0 |
0 |
0 |
0 |
1 |
| Technology platform |
Platform Specific Methodology - Array CGH |
0 |
0 |
0 |
0 |
0 |
5 |
| Template modification |
Platform Specific Methodology - Array CGH |
1 |
0 |
0 |
0 |
0 |
3 |
| Template/input amount |
Platform Specific Methodology - Array CGH |
0 |
0 |
0 |
0 |
0 |
3 |
| Type of array |
Platform Specific Methodology - Array CGH |
0 |
0 |
0 |
0 |
0 |
1 |
| Quality metrics |
Platform Specific Methodology - Automated electrophoresis/Bioanalyzer |
0 |
0 |
0 |
0 |
0 |
10 |
| Technology platform |
Platform Specific Methodology - Automated electrophoresis/Bioanalyzer |
0 |
0 |
1 |
0 |
0 |
2 |
| Template modification |
Platform Specific Methodology - Automated electrophoresis/Bioanalyzer |
0 |
1 |
0 |
0 |
0 |
0 |
| Quality metrics |
Platform Specific Methodology - Bisulfite conversion assay |
0 |
0 |
0 |
0 |
0 |
1 |
| Targeted nucleic acid |
Platform Specific Methodology - Bisulfite conversion assay |
4 |
1 |
3 |
0 |
1 |
3 |
| Technology platform |
Platform Specific Methodology - Bisulfite conversion assay |
2 |
0 |
1 |
0 |
0 |
2 |
| Template modification |
Platform Specific Methodology - Bisulfite conversion assay |
0 |
0 |
0 |
0 |
0 |
2 |
| Technology platform |
Platform Specific Methodology - Branch DNA assay |
2 |
1 |
1 |
0 |
0 |
0 |
| Technology platform |
Platform Specific Methodology - Capillary electrophoresis-MS |
0 |
0 |
1 |
0 |
0 |
1 |
| Detection method |
Platform Specific Methodology - CGH |
0 |
0 |
0 |
0 |
0 |
1 |
| Technology platform |
Platform Specific Methodology - CGH |
0 |
0 |
0 |
0 |
0 |
1 |
| Technology platform |
Platform Specific Methodology - Chemiluminescence immunoassay |
1 |
1 |
1 |
0 |
0 |
0 |
| Analytical algorithm |
Platform Specific Methodology - Clinical chemistry/auto analyzer |
1 |
1 |
1 |
0 |
0 |
0 |
| Data handling |
Platform Specific Methodology - Clinical chemistry/auto analyzer |
1 |
1 |
0 |
0 |
0 |
0 |
| Detection method |
Platform Specific Methodology - Clinical chemistry/auto analyzer |
4 |
5 |
2 |
1 |
0 |
0 |
| Reaction solution |
Platform Specific Methodology - Clinical chemistry/auto analyzer |
0 |
2 |
0 |
0 |
0 |
0 |
| Specimen position |
Platform Specific Methodology - Clinical chemistry/auto analyzer |
0 |
0 |
0 |
0 |
0 |
0 |
| Targeted peptide/protein |
Platform Specific Methodology - Clinical chemistry/auto analyzer |
1 |
1 |
0 |
1 |
0 |
0 |
| Technology platform |
Platform Specific Methodology - Clinical chemistry/auto analyzer |
43 |
35 |
21 |
2 |
0 |
1 |
| Technology platform |
Platform Specific Methodology - Colorimetric assay |
0 |
1 |
0 |
1 |
0 |
0 |
| Type of tissue stain |
Platform Specific Methodology - Colorimetric assay |
0 |
0 |
0 |
0 |
0 |
1 |
| Detection method |
Platform Specific Methodology - Comet assay |
0 |
0 |
0 |
0 |
0 |
1 |
| Reaction solution |
Platform Specific Methodology - Comet assay |
0 |
0 |
0 |
0 |
0 |
1 |
| Template modification |
Platform Specific Methodology - Comet assay |
1 |
0 |
0 |
0 |
0 |
0 |
| Technology platform |
Platform Specific Methodology - Coulter counter |
1 |
0 |
0 |
0 |
0 |
0 |
| Number of probes per gene |
Platform Specific Methodology - DASL |
0 |
0 |
0 |
0 |
0 |
0 |
| Quality metrics |
Platform Specific Methodology - DASL |
0 |
0 |
0 |
0 |
0 |
0 |
| Targeted nucleic acid |
Platform Specific Methodology - DASL |
0 |
0 |
0 |
0 |
0 |
1 |
| Technology platform |
Platform Specific Methodology - DASL |
0 |
0 |
0 |
0 |
0 |
2 |
| Template/input amount |
Platform Specific Methodology - DASL |
0 |
0 |
0 |
0 |
0 |
2 |
| Length of gene fragment |
Platform Specific Methodology - Digital PCR |
6 |
0 |
6 |
0 |
0 |
0 |
| Priming method |
Platform Specific Methodology - Digital PCR |
1 |
0 |
1 |
0 |
0 |
0 |
| Targeted nucleic acid |
Platform Specific Methodology - Digital PCR |
19 |
2 |
30 |
0 |
1 |
5 |
| Technology platform |
Platform Specific Methodology - Digital PCR |
8 |
1 |
14 |
0 |
0 |
2 |
| Template modification |
Platform Specific Methodology - Digital PCR |
3 |
0 |
5 |
0 |
0 |
1 |
| Template/input amount |
Platform Specific Methodology - Digital PCR |
2 |
0 |
4 |
0 |
0 |
1 |
| Analytical algorithm |
Platform Specific Methodology - DNA microarray |
0 |
0 |
0 |
0 |
0 |
1 |
| Data handling |
Platform Specific Methodology - DNA microarray |
4 |
1 |
1 |
0 |
0 |
0 |
| Detection method |
Platform Specific Methodology - DNA microarray |
0 |
0 |
0 |
0 |
0 |
1 |
| Length of gene fragment |
Platform Specific Methodology - DNA microarray |
0 |
0 |
0 |
0 |
0 |
0 |
| Nucleic acid amplification |
Platform Specific Methodology - DNA microarray |
2 |
0 |
0 |
0 |
0 |
2 |
| Quality metrics |
Platform Specific Methodology - DNA microarray |
0 |
0 |
0 |
0 |
0 |
3 |
| RNA incubation temperature |
Platform Specific Methodology - DNA microarray |
0 |
0 |
0 |
0 |
0 |
1 |
| Signal amplification |
Platform Specific Methodology - DNA microarray |
0 |
0 |
0 |
0 |
0 |
2 |
| Targeted nucleic acid |
Platform Specific Methodology - DNA microarray |
0 |
0 |
0 |
0 |
0 |
9 |
| Technology platform |
Platform Specific Methodology - DNA microarray |
3 |
0 |
0 |
0 |
1 |
12 |
| Template modification |
Platform Specific Methodology - DNA microarray |
3 |
0 |
0 |
0 |
0 |
4 |
| Template/input amount |
Platform Specific Methodology - DNA microarray |
0 |
0 |
1 |
0 |
0 |
4 |
| Type of array |
Platform Specific Methodology - DNA microarray |
2 |
0 |
0 |
0 |
0 |
7 |
| Data handling |
Platform Specific Methodology - DNA sequencing |
1 |
0 |
0 |
0 |
0 |
1 |
| Incubation temperature |
Platform Specific Methodology - DNA sequencing |
1 |
0 |
0 |
0 |
0 |
1 |
| Reaction solution |
Platform Specific Methodology - DNA sequencing |
1 |
0 |
0 |
0 |
0 |
1 |
| Targeted nucleic acid |
Platform Specific Methodology - DNA sequencing |
1 |
0 |
0 |
0 |
0 |
12 |
| Technology platform |
Platform Specific Methodology - DNA sequencing |
0 |
0 |
0 |
0 |
0 |
3 |
| Template/input amount |
Platform Specific Methodology - DNA sequencing |
1 |
0 |
0 |
0 |
0 |
4 |
| Type of tissue stain |
Platform Specific Methodology - DNA sequencing |
0 |
0 |
0 |
0 |
0 |
3 |
| Incubation temperature |
Platform Specific Methodology - Dot blot or slot blot |
1 |
0 |
0 |
0 |
0 |
0 |
| Targeted nucleic acid |
Platform Specific Methodology - Dot blot or slot blot |
0 |
0 |
0 |
0 |
0 |
0 |
| Technology platform |
Platform Specific Methodology - Dot blot or slot blot |
0 |
0 |
0 |
0 |
0 |
0 |
| Targeted peptide/protein |
Platform Specific Methodology - Electroimmunoassay |
1 |
1 |
0 |
0 |
0 |
0 |
| Technology platform |
Platform Specific Methodology - Electron microscopy |
0 |
0 |
0 |
1 |
0 |
0 |
| Detection method |
Platform Specific Methodology - Electrophoresis |
0 |
1 |
0 |
0 |
0 |
0 |
| Nucleic acid amplification |
Platform Specific Methodology - Electrophoresis |
0 |
0 |
0 |
0 |
0 |
0 |
| Technology platform |
Platform Specific Methodology - Electrophoresis |
1 |
0 |
0 |
0 |
0 |
0 |
| Type of tissue stain |
Platform Specific Methodology - Electrophoresis |
0 |
0 |
0 |
0 |
0 |
1 |
| Detection method |
Platform Specific Methodology - ELISA |
1 |
0 |
1 |
0 |
0 |
0 |
| Reaction solution |
Platform Specific Methodology - ELISA |
1 |
0 |
1 |
0 |
0 |
0 |
| Specimen position |
Platform Specific Methodology - ELISA |
2 |
1 |
1 |
0 |
0 |
0 |
| Targeted peptide/protein |
Platform Specific Methodology - ELISA |
16 |
13 |
15 |
3 |
0 |
5 |
| Technology platform |
Platform Specific Methodology - ELISA |
6 |
5 |
6 |
1 |
0 |
0 |
| Antibody dilution/concentration |
Platform Specific Methodology - Enzyme assay |
0 |
0 |
0 |
0 |
0 |
0 |
| Detection method |
Platform Specific Methodology - Enzyme assay |
1 |
0 |
1 |
0 |
0 |
0 |
| Incubation time |
Platform Specific Methodology - Enzyme assay |
1 |
0 |
0 |
0 |
0 |
0 |
| Reaction volume |
Platform Specific Methodology - Enzyme assay |
1 |
0 |
1 |
0 |
0 |
2 |
| Technology platform |
Platform Specific Methodology - Enzyme assay |
1 |
1 |
1 |
0 |
0 |
0 |
| Reaction solution |
Platform Specific Methodology - ESI MS |
0 |
0 |
0 |
0 |
0 |
0 |
| Technology platform |
Platform Specific Methodology - ESI MS |
1 |
1 |
1 |
0 |
0 |
0 |
| Technology platform |
Platform Specific Methodology - First-strand cDNA Synthesis |
1 |
0 |
0 |
0 |
0 |
0 |
| Data handling |
Platform Specific Methodology - FISH |
0 |
0 |
0 |
0 |
0 |
2 |
| Post hybridization wash |
Platform Specific Methodology - FISH |
0 |
0 |
0 |
0 |
0 |
1 |
| Targeted nucleic acid |
Platform Specific Methodology - FISH |
2 |
0 |
0 |
0 |
0 |
32 |
| Technology platform |
Platform Specific Methodology - FISH |
0 |
0 |
0 |
0 |
0 |
8 |
| Detection method |
Platform Specific Methodology - Flow cytometry |
1 |
0 |
0 |
0 |
0 |
1 |
| Reaction solution |
Platform Specific Methodology - Flow cytometry |
8 |
0 |
1 |
0 |
0 |
3 |
| Targeted peptide/protein |
Platform Specific Methodology - Flow cytometry |
7 |
0 |
1 |
0 |
0 |
2 |
| Technology platform |
Platform Specific Methodology - Flow cytometry |
5 |
0 |
1 |
1 |
1 |
7 |
| Type of tissue stain |
Platform Specific Methodology - Flow cytometry |
0 |
0 |
0 |
0 |
0 |
2 |
| Targeted nucleic acid |
Platform Specific Methodology - Fluorescent labeled bead assay |
0 |
0 |
0 |
0 |
0 |
1 |
| Detection method |
Platform Specific Methodology - Fluorescent microscopy |
1 |
0 |
0 |
0 |
0 |
0 |
| Targeted peptide/protein |
Platform Specific Methodology - Fluorescent microscopy |
5 |
0 |
0 |
0 |
0 |
1 |
| Technology platform |
Platform Specific Methodology - Fluorescent microscopy |
0 |
0 |
0 |
1 |
0 |
0 |
| Type of tissue stain |
Platform Specific Methodology - Fluorescent microscopy |
1 |
0 |
0 |
0 |
0 |
0 |
| Data handling |
Platform Specific Methodology - Fluorometry |
1 |
0 |
0 |
0 |
0 |
0 |
| Detection method |
Platform Specific Methodology - Fluorometry |
1 |
0 |
0 |
0 |
0 |
0 |
| Frequency of servicing |
Platform Specific Methodology - Fluorometry |
1 |
0 |
0 |
0 |
0 |
0 |
| Technology platform |
Platform Specific Methodology - Fluorometry |
8 |
0 |
14 |
1 |
0 |
4 |
| Template modification |
Platform Specific Methodology - Fluorometry |
1 |
0 |
0 |
0 |
0 |
0 |
| Template/input amount |
Platform Specific Methodology - Fluorometry |
2 |
0 |
0 |
0 |
0 |
1 |
| Type of tissue stain |
Platform Specific Methodology - Fluorometry |
0 |
0 |
0 |
0 |
0 |
1 |
| Nucleic acid amplification |
Platform Specific Methodology - Fluoroscopy |
0 |
0 |
0 |
0 |
0 |
0 |
| Technology platform |
Platform Specific Methodology - GC |
1 |
0 |
0 |
0 |
0 |
0 |
| Technology platform |
Platform Specific Methodology - GC-MS |
0 |
0 |
0 |
0 |
0 |
0 |
| Data handling |
Platform Specific Methodology - H-and-E microscopy |
0 |
0 |
0 |
0 |
0 |
2 |
| Technology platform |
Platform Specific Methodology - H-and-E microscopy |
0 |
0 |
0 |
0 |
0 |
1 |
| Heating method |
Platform Specific Methodology - Hematology/ auto analyzer |
0 |
0 |
1 |
0 |
0 |
0 |
| Incubation temperature |
Platform Specific Methodology - Hematology/ auto analyzer |
0 |
0 |
2 |
0 |
0 |
0 |
| Incubation time |
Platform Specific Methodology - Hematology/ auto analyzer |
0 |
0 |
1 |
0 |
0 |
0 |
| Reaction solution |
Platform Specific Methodology - Hematology/ auto analyzer |
29 |
1 |
20 |
0 |
0 |
2 |
| Targeted peptide/protein |
Platform Specific Methodology - Hematology/ auto analyzer |
1 |
1 |
2 |
0 |
0 |
0 |
| Technology platform |
Platform Specific Methodology - Hematology/ auto analyzer |
25 |
0 |
17 |
0 |
0 |
2 |
| Detection method |
Platform Specific Methodology - HPLC |
1 |
1 |
1 |
0 |
0 |
0 |
| Technology platform |
Platform Specific Methodology - HPLC |
3 |
0 |
3 |
2 |
0 |
1 |
| Reaction solution |
Platform Specific Methodology - Immunoassay |
1 |
1 |
1 |
0 |
0 |
0 |
| Targeted peptide/protein |
Platform Specific Methodology - Immunoassay |
11 |
4 |
4 |
2 |
1 |
6 |
| Technology platform |
Platform Specific Methodology - Immunoassay |
7 |
8 |
7 |
0 |
0 |
2 |
| Antibody dilution/concentration |
Platform Specific Methodology - Immunohistochemistry |
0 |
0 |
0 |
0 |
0 |
9 |
| Data handling |
Platform Specific Methodology - Immunohistochemistry |
0 |
0 |
0 |
0 |
0 |
9 |
| Detection method |
Platform Specific Methodology - Immunohistochemistry |
0 |
0 |
0 |
0 |
0 |
8 |
| Incubation temperature |
Platform Specific Methodology - Immunohistochemistry |
0 |
0 |
0 |
0 |
0 |
3 |
| Incubation time |
Platform Specific Methodology - Immunohistochemistry |
0 |
0 |
0 |
0 |
0 |
4 |
| Reaction solution |
Platform Specific Methodology - Immunohistochemistry |
0 |
0 |
0 |
0 |
0 |
2 |
| Signal amplification |
Platform Specific Methodology - Immunohistochemistry |
0 |
0 |
0 |
0 |
0 |
1 |
| Targeted peptide/protein |
Platform Specific Methodology - Immunohistochemistry |
9 |
1 |
1 |
0 |
0 |
207 |
| Technology platform |
Platform Specific Methodology - Immunohistochemistry |
0 |
0 |
1 |
0 |
0 |
20 |
| Type of antibody |
Platform Specific Methodology - Immunohistochemistry |
0 |
0 |
0 |
0 |
0 |
17 |
| Technology platform |
Platform Specific Methodology - Immunoradiometric assay |
1 |
1 |
1 |
0 |
0 |
0 |
| Technology platform |
Platform Specific Methodology - Immunoturbidometric assay |
1 |
0 |
1 |
0 |
0 |
0 |
| Data handling |
Platform Specific Methodology - In situ hybridization |
0 |
0 |
0 |
0 |
0 |
1 |
| Detection method |
Platform Specific Methodology - In situ hybridization |
0 |
0 |
0 |
0 |
0 |
1 |
| Nucleic acid amplification |
Platform Specific Methodology - In situ hybridization |
0 |
0 |
0 |
0 |
0 |
1 |
| Signal amplification |
Platform Specific Methodology - In situ hybridization |
0 |
0 |
0 |
0 |
0 |
1 |
| Targeted nucleic acid |
Platform Specific Methodology - In situ hybridization |
2 |
0 |
0 |
0 |
0 |
25 |
| Technology platform |
Platform Specific Methodology - In situ hybridization |
0 |
0 |
0 |
0 |
0 |
4 |
| Type of probe |
Platform Specific Methodology - In situ hybridization |
0 |
0 |
0 |
0 |
0 |
2 |
| Technology platform |
Platform Specific Methodology - Ion selective electrode |
1 |
1 |
0 |
0 |
0 |
0 |
| Reaction solution |
Platform Specific Methodology - LC-ESI-MS/MS |
0 |
0 |
0 |
0 |
0 |
1 |
| Technology platform |
Platform Specific Methodology - LC-ESI-MS/MS |
0 |
0 |
0 |
0 |
0 |
2 |
| Detection method |
Platform Specific Methodology - LC-MS or LC-MS/MS |
1 |
1 |
0 |
0 |
0 |
1 |
| Targeted peptide/protein |
Platform Specific Methodology - LC-MS or LC-MS/MS |
0 |
1 |
1 |
0 |
0 |
2 |
| Technology platform |
Platform Specific Methodology - LC-MS or LC-MS/MS |
3 |
2 |
5 |
1 |
0 |
2 |
| Template/input amount |
Platform Specific Methodology - LC-MS or LC-MS/MS |
0 |
0 |
0 |
0 |
0 |
1 |
| Data handling |
Platform Specific Methodology - Light microscopy |
0 |
0 |
0 |
0 |
0 |
1 |
| Experimental Bias |
Platform Specific Methodology - Light microscopy |
0 |
0 |
0 |
0 |
0 |
0 |
| Technology platform |
Platform Specific Methodology - Light microscopy |
1 |
1 |
1 |
0 |
0 |
1 |
| Type of tissue stain |
Platform Specific Methodology - Light microscopy |
0 |
0 |
0 |
0 |
0 |
5 |
| Data handling |
Platform Specific Methodology - Low density array |
1 |
0 |
2 |
0 |
0 |
1 |
| Targeted nucleic acid |
Platform Specific Methodology - Low density array |
2 |
2 |
1 |
0 |
0 |
4 |
| Technology platform |
Platform Specific Methodology - Low density array |
0 |
0 |
0 |
0 |
0 |
1 |
| Type of array |
Platform Specific Methodology - Low density array |
2 |
1 |
2 |
0 |
0 |
2 |
| Reaction solution |
Platform Specific Methodology - Macroscopic observation |
1 |
0 |
1 |
0 |
0 |
0 |
| Targeted peptide/protein |
Platform Specific Methodology - Macroscopic observation |
1 |
0 |
0 |
0 |
0 |
0 |
| Data handling |
Platform Specific Methodology - MALDI-TOF MS |
1 |
1 |
0 |
0 |
0 |
0 |
| Detection method |
Platform Specific Methodology - MALDI-TOF MS |
1 |
1 |
0 |
1 |
0 |
0 |
| Reaction solution |
Platform Specific Methodology - MALDI-TOF MS |
1 |
1 |
0 |
0 |
0 |
1 |
| Resin |
Platform Specific Methodology - MALDI-TOF MS |
1 |
1 |
1 |
2 |
0 |
0 |
| Targeted nucleic acid |
Platform Specific Methodology - MALDI-TOF MS |
0 |
0 |
0 |
0 |
0 |
1 |
| Targeted peptide/protein |
Platform Specific Methodology - MALDI-TOF MS |
1 |
1 |
1 |
0 |
0 |
0 |
| Technology platform |
Platform Specific Methodology - MALDI-TOF MS |
1 |
1 |
0 |
0 |
0 |
2 |
| Template modification |
Platform Specific Methodology - MALDI-TOF MS |
1 |
1 |
0 |
0 |
0 |
0 |
| Template/input amount |
Platform Specific Methodology - MALDI-TOF MS |
0 |
0 |
0 |
1 |
0 |
0 |
| Type of tissue stain |
Platform Specific Methodology - MALDI-TOF MS |
0 |
0 |
0 |
0 |
0 |
0 |
| Technology platform |
Platform Specific Methodology - Microbiological assay |
1 |
1 |
0 |
5 |
0 |
0 |
| Nucleic acid amplification |
Platform Specific Methodology - Microsatellite analysis |
1 |
0 |
0 |
0 |
0 |
1 |
| Number of cycles |
Platform Specific Methodology - Microsatellite analysis |
1 |
0 |
0 |
0 |
0 |
1 |
| Targeted nucleic acid |
Platform Specific Methodology - Microsatellite analysis |
0 |
0 |
0 |
0 |
1 |
0 |
| Technology platform |
Platform Specific Methodology - Microsatellite analysis |
1 |
0 |
0 |
0 |
1 |
0 |
| Targeted peptide/protein |
Platform Specific Methodology - MS/MS |
1 |
0 |
0 |
0 |
0 |
0 |
| Technology platform |
Platform Specific Methodology - MS/MS |
1 |
0 |
0 |
0 |
0 |
1 |
| Data handling |
Platform Specific Methodology - Next generation sequencing |
4 |
0 |
3 |
0 |
0 |
9 |
| Length of gene fragment |
Platform Specific Methodology - Next generation sequencing |
0 |
0 |
0 |
0 |
0 |
2 |
| Nucleic acid amplification |
Platform Specific Methodology - Next generation sequencing |
2 |
0 |
1 |
0 |
0 |
4 |
| Priming method |
Platform Specific Methodology - Next generation sequencing |
0 |
0 |
1 |
0 |
0 |
1 |
| Reaction solution |
Platform Specific Methodology - Next generation sequencing |
0 |
0 |
0 |
0 |
0 |
2 |
| Targeted nucleic acid |
Platform Specific Methodology - Next generation sequencing |
2 |
0 |
6 |
0 |
0 |
8 |
| Technology platform |
Platform Specific Methodology - Next generation sequencing |
5 |
1 |
19 |
2 |
1 |
47 |
| Template modification |
Platform Specific Methodology - Next generation sequencing |
2 |
0 |
3 |
0 |
0 |
18 |
| Template/input amount |
Platform Specific Methodology - Next generation sequencing |
5 |
1 |
6 |
0 |
0 |
17 |
| Type of tissue stain |
Platform Specific Methodology - Next generation sequencing |
0 |
0 |
0 |
0 |
0 |
3 |
| Targeted nucleic acid |
Platform Specific Methodology - Northern blot |
0 |
0 |
0 |
0 |
0 |
4 |
| Denaturation |
Platform Specific Methodology - PCR |
0 |
0 |
0 |
0 |
0 |
0 |
| Detection method |
Platform Specific Methodology - PCR |
0 |
0 |
1 |
0 |
0 |
1 |
| Length of gene fragment |
Platform Specific Methodology - PCR |
8 |
1 |
4 |
1 |
5 |
81 |
| Ligation |
Platform Specific Methodology - PCR |
0 |
0 |
0 |
0 |
0 |
0 |
| Nucleic acid amplification |
Platform Specific Methodology - PCR |
2 |
1 |
1 |
0 |
0 |
4 |
| Number of cycles |
Platform Specific Methodology - PCR |
1 |
0 |
0 |
0 |
0 |
2 |
| Reaction solution |
Platform Specific Methodology - PCR |
1 |
1 |
1 |
0 |
0 |
3 |
| Targeted nucleic acid |
Platform Specific Methodology - PCR |
7 |
2 |
3 |
1 |
1 |
87 |
| Technology platform |
Platform Specific Methodology - PCR |
2 |
1 |
1 |
1 |
0 |
8 |
| Template/input amount |
Platform Specific Methodology - PCR |
2 |
0 |
0 |
0 |
0 |
5 |
| Type of tissue stain |
Platform Specific Methodology - PCR |
0 |
0 |
0 |
1 |
0 |
8 |
| Targeted nucleic acid |
Platform Specific Methodology - PHFA |
0 |
0 |
1 |
0 |
0 |
1 |
| Reaction solution |
Platform Specific Methodology - Photometer |
1 |
0 |
0 |
0 |
0 |
0 |
| Technology platform |
Platform Specific Methodology - Photometer |
1 |
0 |
0 |
0 |
0 |
0 |
| Antigen |
Platform Specific Methodology - Radioassay |
1 |
0 |
0 |
0 |
0 |
1 |
| Detection method |
Platform Specific Methodology - Radioassay |
1 |
0 |
0 |
0 |
0 |
0 |
| Targeted peptide/protein |
Platform Specific Methodology - Radioassay |
0 |
0 |
0 |
0 |
0 |
1 |
| Incubation time |
Platform Specific Methodology - Radioimmunoassay |
1 |
1 |
0 |
0 |
0 |
0 |
| Technology platform |
Platform Specific Methodology - Radioimmunoassay |
2 |
4 |
1 |
1 |
0 |
0 |
| Data handling |
Platform Specific Methodology - Real-time qPCR |
0 |
0 |
0 |
1 |
0 |
0 |
| Detection method |
Platform Specific Methodology - Real-time qPCR |
2 |
0 |
3 |
0 |
0 |
1 |
| Length of gene fragment |
Platform Specific Methodology - Real-time qPCR |
7 |
2 |
12 |
3 |
1 |
11 |
| Nucleic acid amplification |
Platform Specific Methodology - Real-time qPCR |
0 |
0 |
1 |
0 |
0 |
0 |
| Priming method |
Platform Specific Methodology - Real-time qPCR |
0 |
0 |
0 |
0 |
0 |
0 |
| Quality metrics |
Platform Specific Methodology - Real-time qPCR |
0 |
0 |
0 |
0 |
0 |
3 |
| Signal amplification |
Platform Specific Methodology - Real-time qPCR |
0 |
0 |
0 |
0 |
0 |
0 |
| Specimen position |
Platform Specific Methodology - Real-time qPCR |
0 |
0 |
1 |
0 |
0 |
0 |
| Targeted nucleic acid |
Platform Specific Methodology - Real-time qPCR |
44 |
15 |
59 |
7 |
5 |
46 |
| Technology platform |
Platform Specific Methodology - Real-time qPCR |
5 |
5 |
13 |
0 |
0 |
8 |
| Template modification |
Platform Specific Methodology - Real-time qPCR |
1 |
0 |
0 |
0 |
0 |
0 |
| Template/input amount |
Platform Specific Methodology - Real-time qPCR |
3 |
0 |
2 |
0 |
1 |
6 |
| Type of array |
Platform Specific Methodology - Real-time qPCR |
0 |
0 |
0 |
0 |
0 |
0 |
| Type of tissue stain |
Platform Specific Methodology - Real-time qPCR |
0 |
0 |
0 |
0 |
0 |
1 |
| Analytical algorithm |
Platform Specific Methodology - Real-time qRT-PCR |
0 |
0 |
1 |
0 |
0 |
1 |
| Data handling |
Platform Specific Methodology - Real-time qRT-PCR |
8 |
5 |
9 |
2 |
0 |
5 |
| Detection method |
Platform Specific Methodology - Real-time qRT-PCR |
0 |
0 |
0 |
0 |
0 |
2 |
| Expression of gene clusters |
Platform Specific Methodology - Real-time qRT-PCR |
0 |
0 |
0 |
0 |
0 |
0 |
| Length of gene fragment |
Platform Specific Methodology - Real-time qRT-PCR |
2 |
0 |
0 |
0 |
1 |
18 |
| Nucleic acid amplification |
Platform Specific Methodology - Real-time qRT-PCR |
1 |
2 |
2 |
0 |
0 |
2 |
| Priming method |
Platform Specific Methodology - Real-time qRT-PCR |
0 |
0 |
0 |
0 |
0 |
4 |
| Quality metrics |
Platform Specific Methodology - Real-time qRT-PCR |
0 |
0 |
0 |
0 |
0 |
1 |
| Reaction solution |
Platform Specific Methodology - Real-time qRT-PCR |
0 |
0 |
0 |
0 |
0 |
0 |
| Specimen position |
Platform Specific Methodology - Real-time qRT-PCR |
0 |
0 |
0 |
0 |
0 |
0 |
| Targeted nucleic acid |
Platform Specific Methodology - Real-time qRT-PCR |
85 |
31 |
55 |
9 |
12 |
186 |
| Technology platform |
Platform Specific Methodology - Real-time qRT-PCR |
9 |
6 |
9 |
0 |
1 |
16 |
| Template modification |
Platform Specific Methodology - Real-time qRT-PCR |
4 |
2 |
5 |
2 |
0 |
2 |
| Template/input amount |
Platform Specific Methodology - Real-time qRT-PCR |
1 |
2 |
4 |
0 |
0 |
4 |
| Type of array |
Platform Specific Methodology - Real-time qRT-PCR |
0 |
0 |
0 |
0 |
0 |
2 |
| Type of tissue stain |
Platform Specific Methodology - Real-time qRT-PCR |
0 |
0 |
0 |
0 |
0 |
1 |
| Reaction solution |
Platform Specific Methodology - Receptor binding |
0 |
0 |
0 |
0 |
0 |
1 |
| Targeted peptide/protein |
Platform Specific Methodology - Receptor binding |
0 |
0 |
0 |
0 |
0 |
2 |
| Targeted nucleic acid |
Platform Specific Methodology - Restriction fragment length polymorphism |
0 |
0 |
0 |
0 |
1 |
1 |
| Template modification |
Platform Specific Methodology - Restriction fragment length polymorphism |
0 |
0 |
0 |
1 |
0 |
1 |
| Targeted peptide/protein |
Platform Specific Methodology - Reverse phase protein microarray |
0 |
1 |
0 |
0 |
0 |
4 |
| Technology platform |
Platform Specific Methodology - Reverse phase protein microarray |
0 |
0 |
0 |
0 |
0 |
2 |
| Nucleic acid amplification |
Platform Specific Methodology - RNA amplification |
0 |
0 |
0 |
0 |
0 |
1 |
| Detection method |
Platform Specific Methodology - RT-PCR |
0 |
0 |
0 |
0 |
0 |
0 |
| Incubation time |
Platform Specific Methodology - RT-PCR |
0 |
0 |
0 |
0 |
0 |
1 |
| Length of gene fragment |
Platform Specific Methodology - RT-PCR |
0 |
0 |
0 |
1 |
0 |
35 |
| Number of cycles |
Platform Specific Methodology - RT-PCR |
0 |
0 |
0 |
0 |
0 |
1 |
| Priming method |
Platform Specific Methodology - RT-PCR |
0 |
0 |
0 |
0 |
0 |
2 |
| Reaction solution |
Platform Specific Methodology - RT-PCR |
1 |
0 |
0 |
0 |
0 |
2 |
| RNA incubation temperature |
Platform Specific Methodology - RT-PCR |
0 |
0 |
0 |
0 |
0 |
4 |
| Targeted nucleic acid |
Platform Specific Methodology - RT-PCR |
19 |
3 |
7 |
1 |
0 |
50 |
| Technology platform |
Platform Specific Methodology - RT-PCR |
4 |
1 |
4 |
0 |
0 |
3 |
| Template modification |
Platform Specific Methodology - RT-PCR |
1 |
0 |
1 |
0 |
0 |
1 |
| Type of tissue stain |
Platform Specific Methodology - RT-PCR |
0 |
0 |
0 |
1 |
0 |
1 |
| Antigen |
Platform Specific Methodology - Scanning acoustic microscopy |
0 |
0 |
0 |
0 |
0 |
0 |
| Denaturation |
Platform Specific Methodology - SELDI-TOF MS |
0 |
0 |
0 |
0 |
1 |
0 |
| Detection method |
Platform Specific Methodology - SELDI-TOF MS |
0 |
0 |
0 |
0 |
1 |
0 |
| Reaction solution |
Platform Specific Methodology - SELDI-TOF MS |
0 |
0 |
0 |
2 |
0 |
0 |
| Resin |
Platform Specific Methodology - SELDI-TOF MS |
0 |
1 |
0 |
0 |
0 |
0 |
| Technology platform |
Platform Specific Methodology - SELDI-TOF MS |
2 |
2 |
1 |
1 |
0 |
0 |
| Type of array |
Platform Specific Methodology - SELDI-TOF MS |
2 |
5 |
1 |
3 |
1 |
0 |
| Detection method |
Platform Specific Methodology - SNP assay |
0 |
0 |
0 |
0 |
0 |
1 |
| Nucleic acid amplification |
Platform Specific Methodology - SNP assay |
3 |
0 |
0 |
0 |
1 |
4 |
| Reaction solution |
Platform Specific Methodology - SNP assay |
0 |
0 |
0 |
0 |
0 |
1 |
| Targeted nucleic acid |
Platform Specific Methodology - SNP assay |
2 |
0 |
0 |
0 |
3 |
11 |
| Technology platform |
Platform Specific Methodology - SNP assay |
3 |
0 |
1 |
0 |
1 |
6 |
| Template modification |
Platform Specific Methodology - SNP assay |
0 |
0 |
0 |
0 |
0 |
1 |
| Template/input amount |
Platform Specific Methodology - SNP assay |
0 |
0 |
0 |
0 |
0 |
1 |
| Detection method |
Platform Specific Methodology - Southern blot |
0 |
0 |
0 |
0 |
0 |
1 |
| Targeted nucleic acid |
Platform Specific Methodology - Southern blot |
3 |
1 |
1 |
0 |
0 |
4 |
| Data handling |
Platform Specific Methodology - Spectrophotometry |
2 |
1 |
1 |
0 |
0 |
0 |
| Frequency of servicing |
Platform Specific Methodology - Spectrophotometry |
1 |
0 |
0 |
0 |
0 |
0 |
| Quality metrics |
Platform Specific Methodology - Spectrophotometry |
0 |
0 |
0 |
0 |
0 |
3 |
| Technology platform |
Platform Specific Methodology - Spectrophotometry |
15 |
4 |
5 |
0 |
2 |
17 |
| Template modification |
Platform Specific Methodology - Spectrophotometry |
1 |
0 |
0 |
0 |
0 |
0 |
| Template/input amount |
Platform Specific Methodology - Spectrophotometry |
2 |
0 |
0 |
0 |
0 |
2 |
| Construction order |
Platform Specific Methodology - Tissue microarray |
0 |
0 |
0 |
0 |
0 |
1 |
| Data handling |
Platform Specific Methodology - Tissue microarray |
0 |
0 |
0 |
0 |
0 |
5 |
| Specimen position |
Platform Specific Methodology - Tissue microarray |
0 |
0 |
0 |
0 |
0 |
1 |
| Targeted peptide/protein |
Platform Specific Methodology - Tissue microarray |
0 |
0 |
0 |
0 |
0 |
3 |
| Technology platform |
Platform Specific Methodology - Tissue microarray |
0 |
0 |
0 |
0 |
0 |
0 |
| Incubation time |
Platform Specific Methodology - Western blot |
0 |
0 |
0 |
0 |
0 |
1 |
| Targeted peptide/protein |
Platform Specific Methodology - Western blot |
6 |
6 |
7 |
4 |
2 |
27 |
| Type of tissue stain |
Platform Specific Methodology - Western blot |
0 |
0 |
0 |
0 |
0 |
1 |
| Nucleic acid amplification |
Platform Specific Methodology - Whole genome amplification |
5 |
1 |
3 |
0 |
1 |
13 |
| Template modification |
Platform Specific Methodology - Whole genome amplification |
0 |
0 |
0 |
0 |
0 |
1 |
| Template/input amount |
Platform Specific Methodology - Whole genome amplification |
1 |
0 |
1 |
0 |
0 |
2 |
| Nucleic acid amplification |
Platform Specific Methodology - Whole transcriptome amplification |
0 |
0 |
0 |
0 |
0 |
2 |
